JuSun
- AIM ImmunoTech (NYSE:AIM) jumped ~17% in the morning hours Tuesday after announcing a collaboration with Erasmus University Medical Center and AstraZeneca (AZN) for an investigator-initiated study for its lead asset Ampligen (rintatolimod).
- According to the agreement, Erasmus MC will run the study to evaluate rintatolimod in combination with AstraZeneca’s (AZN) immune checkpoint inhibitor durvalumab in patients with metastatic pancreatic ductal adenocarcinoma.
- AIM ImmunoTech (AIM) and AstraZeneca (AZN) are expected to provide their respective study drugs for the trial.
- The company said that Ampligen has previously indicated pre-clinical synergistic effects with checkpoint inhibitors improving survival rates and efficacy in animal tumors.
- In November, AIM ImmunoTech (AIM) shares surged after the company announced the FDA orphan drug designation for Ampligen to treat Ebola.